Type 1 Diabetes: Epidemiology Forecast to 2033

T1D, formally referred to as insulin-dependent diabetes or juvenile diabetes, is a chronic autoimmune disease that predominantly develops in childhood and young adulthood and accounts for approximately 5-10% of all diabetes cases. It is caused by the body’s immune system destroying pancreatic beta cells, which are responsible for producing a hormone that regulates blood sugar levels called insulin (Mobasseri et al., 2020). If T1D is left untreated, blood sugar levels increase, which can damage the pancreas and other organs (Mayo Clinic, 2024). As T1D is a chronic condition, it has a significant impact on the physical, psychological, and social wellbeing of patients.

Scope

The Type 1 Diabetes Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and the global and historical trends of type 1 diabetes (T1D) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report includes a 10-year epidemiology forecast for T1D, segmented by age, sex, body mass index (BMI) (underweight/normal [BMI < 25kg/m²], overweight [BMI 25-30kg/m²], and obese [BMI ≥30kg/m²]), hypoglycemic events (hypoglycemic and severe hypoglycemic events), brittle diabetes, diabetic ketoacidosis (DKA) events, and having at least one gene encoding for HLA-DQ8 for men and women of all ages. Additionally, the report also provides a 10-year epidemiological forecast for the diagnosed prevalent cases of T1D eligible for pancreas transplantation, with chronic kidney disease (CKD), and with cardiovascular disease (CVD) for men and women over 20 years old. The report also includes total prevalent cases of T1D for men and women of all ages.

Reasons to Buy

The T1D Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global T1D markets.
Quantify patient populations in the global T1D markets to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups, sex, BMI groups, disease conditions and genetic groups that present the best opportunities for T1D therapeutics in each of the markets covered.
Understand magnitude of the T1D population by age, sex, BMI groups, associated disease conditions, pancreas transplant eligibility, and genetic groups.

About the Analyst

1 Type 1 Diabetes (T1D): Executive Summary

1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2 Epidemiology

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 7MM forecast methodology
2.4.1 Sources
2.4.2 Forecast assumptions and methods
2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of T1D - 7MM
2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of T1D
2.4.5 Diagnosed prevalent cases of T1D segmented by BMI
2.4.6 Diagnosed prevalent cases of T1D that experienced hypoglycemic events
2.4.7 Diagnosed prevalent cases of T1D with brittle diabetes
2.4.8 Diagnosed prevalent cases of T1D that experienced DKA events
2.4.9 Diagnosed prevalent cases of T1D eligible for pancreas transplantation
2.4.10 Diagnosed prevalent cases of T1D with CKD
2.4.11 Diagnosed prevalent cases of T1D with CVD
2.4.12 Diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8
2.4.13 Forecast assumptions and methods: total prevalent cases of T1D
2.5 Epidemiological forecast for T1D (2023-33)
2.5.1 Diagnosed prevalent cases of T1D
2.5.2 Age-specific diagnosed prevalent cases of T1D
2.5.3 Sex-specific diagnosed prevalent cases of T1D
2.5.4 Diagnosed prevalent cases of T1D by BMI category
2.5.5 Diagnosed prevalent cases of T1D that experienced hypoglycemic events
2.5.6 Diagnosed prevalent cases of T1D with brittle diabetes
2.5.7 Diagnosed prevalent cases of T1D that experienced DKA events
2.5.8 Diagnosed prevalent cases of T1D eligible for pancreas transplantation
2.5.9 Diagnosed prevalent cases of T1D with CKD
2.5.10 Diagnosed prevalent cases of T1D with CVD
2.5.11 Diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8
2.5.12 Total prevalent cases of T1D
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 COVID-19 impact
2.6.3 Limitations of the analysis
2.6.4 Strengths of the analysis

3 Appendix

3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Vice President of Disease Intelligence and Epidemiology
3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence

Contact the Publisher

List of Tables

Table 1: Summary of newly added data types
Table 2: Summary of updated data types
Table 3: Diagnostic tests commonly used for T1D
Table 4: Risk factors and comorbidities for T1D

List of Figures

Figure 1: 7MM, diagnosed prevalent cases of T1D, all ages, both sexes, N, 2023 and 2033
Figure 2: 7MM, total prevalent cases of T1D, all ages, both sexes, N, 2023 and 2033
Figure 3: 7MM, diagnosed prevalence of T1D, men and women, %, all ages, 2023
Figure 4: 7MM, total prevalence of T1D, men and women, %, all ages, 2023
Figure 5: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D
Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of T1D segmented by BMI category
Figure 7: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D that experienced hypoglycemia
Figure 8: 7MM, source used to forecast the diagnosed prevalent cases of T1D with brittle diabetes
Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D that experienced DKA
Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of T1D that are eligible for a pancreas transplant
Figure 11: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D with CKD
Figure 12: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D with CVD
Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8
Figure 14: 7MM, sources used to forecast the total prevalent cases of T1D
Figure 15: 7MM, diagnosed prevalent cases of T1D, N, both sexes, all ages, 2023
Figure 16: 7MM, diagnosed prevalent cases of T1D by age, N, both sexes, 2023
Figure 17: 7MM, diagnosed prevalent cases of T1D by sex, N, all ages, 2023
Figure 18: 7MM, diagnosed prevalent cases of T1D by BMI category, N, both sexes, all ages, 2023
Figure 19: 7MM, diagnosed prevalent cases of T1D that experienced hypoglycemic events, N, both sexes, all ages, 2023
Figure 20: 7MM, diagnosed prevalent cases of T1D with brittle diabetes, N, both sexes, all ages, 2023
Figure 21: 7MM, diagnosed prevalent cases of T1D that experienced DKA, N, both sexes, all ages, 2023
Figure 22: 7MM, diagnosed prevalent cases of T1D eligible for pancreas transplantation, N, both sexes, =20 years, 2023
Figure 23: 7MM, diagnosed prevalent cases of T1D with CKD, N, both sexes, all ages, 2023
Figure 24: 7MM, diagnosed prevalent cases of T1D with CVD, N, both sexes, all ages, 2023
Figure 25: 7MM, diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8, N, both sexes, all ages, 2023
Figure 26: 7MM, total prevalent cases of T1D, N, both sexes, all ages, 2023

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3943EUR$3,995USD£3,270GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7887EUR$7,990USD£6,540GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€11830EUR$11,985USD£9,810GBP

Scope

Reasons to Buy

The T1D Epidemiology series will allow you to:

Table of Contents

Related Topics

Related Reports

Connected Diabetes Care: Innovations and Growth Opportunities

Diabetes Insipidus - Market Insight, Epidemiology and Market Forecast - 2034

Pediatric Diabetes Therapeutic Market Size, Share and Trends Analysis Report by Type (Type 1, Type 2), Treatment (Insulin, GLP-1, Biguanide, SGLT2), Route of Administration, Distribution Channel, and Region 2024-2030

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast

Diabetes Care Nutrition Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application